Ubiquitination in host immune response to human papillomavirus infection

Archives of Dermatological Research

Volumn 303, Issue 4, 2011, Pages 217-230

  Zhou, Qiang ^a   Zhu, Kejian ^a   Cheng, Hao ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Adaptive immunity; HPV; Innate immunity; Ubiquitin; Ubiquitination

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEIN KINASE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN;

ADAPTIVE IMMUNITY; GENE ACTIVATION; GENE CONTROL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; VIRUS IMMUNITY;

ADAPTIVE IMMUNITY; ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; IMMUNITY, INNATE; PAPILLOMAVIRUS INFECTIONS; UBIQUITINATION; UTERINE CERVICAL NEOPLASMS;

EID: 79955893891     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-011-1141-0     Document Type: Review

References (120)

1. Andersen MW, Ballal NR, Goldknopf IL, Busch H (1981) Protein A24 lyase activity in nucleoli of thioacetamide-treated rat liver releases histone 2A and ubiquitin from conjugated protein A24. Biochemistry 20(5):1100-1104
2. Ang XL, Wade Harper J (2005) SCF-mediated protein degradation and cell cycle control. Oncogene 24(17):2860-2870 (Pubitemid 40638095)
3. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, Le J, Ohashi PS, Sarosi I, Nishina H, Lipkowitz S, Penninger JM (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403(6766):211-216 (Pubitemid 30050966)
4. Balkwill F (2006) TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25(3):409-416
5. Beaudenon S, Huibregtse JM (2008) HPV E6, E6AP and cervical cancer. BMC Biochem 9(Suppl 1):S4
6. Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274(5288):782-784 (Pubitemid 26398258)
7. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30(6):689-700 (Pubitemid 351818251)
8. Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430(6996):257-263
9. Bhoj VG, Chen ZJ (2009) Ubiquitylation in innate and adaptive immunity. Nature 458(7237):430-437
10. Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214(2):149-160
11. Call ME, Wucherpfennig KW (2005) The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol 23:101-125 (Pubitemid 40563166)
12. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72(9):3666-3670
13. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M (2006) The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124(3):601-613 (Pubitemid 43199444)
14. Chen XZ, Mao XH, Zhu KJ, Jin N, Ye J, Cen JP, Zhou Q, Cheng H (2010) Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells. Arch Dermatol Res 302(1):57-65
15. Chen ZJ (2005) Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7(8):758-765
16. Chen ZJ, Parent L, Maniatis T (1996) Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell 84(6):853-862 (Pubitemid 26106855)
17. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E, Gu H (2000) Cbl-b regulates the CD28 dependence of T cell activation. Nature 403(6766):216-220 (Pubitemid 30050967)
18. Chuang TH, Ulevitch RJ (2004) Triad3A, an E3 ubiquitinprotein ligase regulating Toll-like receptors. Nat Immunol 5(5): 495-502
19. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79(1):13-21
20. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324(1):17-27 (Pubitemid 38737395)
21. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ (2000) Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103(2):351-361
22. Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cancer. Virchows Arch 446(5):475-482 (Pubitemid 40884279)
23. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33-42
24. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850-854 (Pubitemid 35231542)
25. Duwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D (2009) A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 182(12):7718-7728
26. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ (2006) Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 22(2):245-257
27. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D (2009) Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 9(6):347-356
28. Elliott PJ, Zollner TM, Boehncke WH (2003) Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81(4):235-245 (Pubitemid 36578922)
29. Fahey LM, Raff AB, Da Silva DM, Kast WM (2009) Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol 182(5):2919-2928
30. Fausch SC, Da Silva DM, Rudolf MP, Kast WM (2002) Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 169(6):3242-3249 (Pubitemid 35013171)
31. Filippova M, Brown-Bryan TA, Casiano CA, Duerksen-Hughes PJ (2005) The human papillomavirus 16 E6 protein can either protect or further sensitize cells to TNF: effect of dose. Cell Death Differ 12(12):1622-1635 (Pubitemid 41679167)
32. Filippova M, Filippov VA, Kagoda M, Garnett T, Fodor N, Duerksen-Hughes PJ (2009) Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis. J Virol 83(1):210-227
33. Filippova M, Parkhurst L, Duerksen-Hughes PJ (2004) The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 279(24):25729-25744 (Pubitemid 38756837)
34. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen- Hughes PJ (2002) The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 277(24):21730-21739 (Pubitemid 34952324)
35. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T (2003) IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4(5):491-496 (Pubitemid 36592443)
36. Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92(18):1500-1510
37. Fukushima T, Matsuzawa S, Kress CL, Bruey JM, Krajewska M, Lefebvre S, Zapata JM, Ronai Z, Reed JC (2007) Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci USA 104(15):6371-6376 (Pubitemid 47186101)
38. Garnett TO, Filippova M, Duerksen-Hughes PJ (2006) Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 13(11):1915-1926 (Pubitemid 44542404)
39. Gaur U, Aggarwal BB (2003) Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66(8):1403-1408 (Pubitemid 38373326)
40. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82(2):373-428 (Pubitemid 34654457)
41. Gruber T, Hermann-Kleiter N, Hinterleitner R, Fresser F, Schneider R, Gastl G, Penninger JM, Baier G (2009) PKC-theta modulates the strength of T cell responses by targeting Cbl-b for ubiquitination and degradation. Sci Signal 2(76):ra30
42. Guedat P, Colland F (2007) Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem 8(Suppl 1):S14
43. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178(5):3186-3197 (Pubitemid 46333201)
44. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18(18):2195-2224
45. Ingham RJ, Gish G, Pawson T (2004) The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene 23(11):1972-1984 (Pubitemid 38496727)
46. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216
47. Jiang Z, Mak TW, Sen G, Li X (2004) Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFNbeta. Proc Natl Acad Sci USA 101(10):3533-3538 (Pubitemid 38338230)
48. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC (1999) The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286(5438):309-312
49. Johnson ES, Ma PC, Ota IM, Varshavsky A (1995) A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 270(29):17442-17456
50. Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A, Chiu YH, Deng L, Chen ZJ (2004) TAB 2 and TAB 3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 15(4):535-548 (Pubitemid 39141781)
51. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5(10):1061-1068 (Pubitemid 41057726)
52. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN (2001) Immunotherapy through TCR gene transfer. Nat Immunol 2(10):957-961 (Pubitemid 32976169)
53. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angstrom T, Dillner J (2000) Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 82(7):1332-1338 (Pubitemid 30145354)
54. Klausner RD, Lippincott-Schwartz J, Bonifacino JS (1990) The T cell antigen receptor: insights into organelle biology. Annu Rev Cell Biol 6:403-431
55. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347(21):1645-1651 (Pubitemid 35340782)
56. Krappmann D, Scheidereit C (2005) A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep 6(4):321-326 (Pubitemid 40561623)
57. Kuhns MS, Davis MM, Garcia KC (2006) Deconstructing the form and function of the TCR/CD3 complex. Immunity 24(2):133-139 (Pubitemid 43214583)
58. Kumar H, Kawai T, Akira S (2009) Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388(4):621-625
59. Latres E, Chiaur DS, Pagano M (1999) The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18(4):849-854 (Pubitemid 29086261)
60. Le Bon A, Tough DF (2002) Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14(4):432-436 (Pubitemid 34671244)
61. Lee TH, Shank J, Cusson N, Kelliher MA (2004) The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem 279(32):33185-33191 (Pubitemid 39062963)
62. Lin CH, Chang HS, Yu WC (2008) USP11 stabilizes HPV-16E7 and further modulates the E7 biological activity. J Biol Chem 283(23):15681-15688
63. Lin X, Wang D (2004) The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. Semin Immunol 16(6):429-435
64. Liu HH, Xie M, Schneider MD, Chen ZJ (2006) Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci USA 103(31):11677-11682 (Pubitemid 44182510)
65. Mammas IN, Sourvinos G, Giannoudis A, Spandidos DA (2008) Human papilloma virus (HPV) and host cellular interactions. Pathol Oncol Res 14(4):345-354
66. Micheau O, Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114(2):181-190 (Pubitemid 36936912)
67. Miller RL, Meng TC, Tomai MA (2008) The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 21(2):69-87 (Pubitemid 351628232)
68. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78(21):11451-11460 (Pubitemid 39390733)
69. Nalepa G, Rolfe M, Harper JW (2006) Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5(7):596-613
70. Oeckinghaus A, Wegener E, Welteke V, Ferch U, Arslan SC, Ruland J, Scheidereit C, Krappmann D (2007) Malt1 ubiquitination triggers NF-kappaB signaling upon T cell activation. EMBO J 26(22):4634-4645 (Pubitemid 350126802)
71. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78(5):773-785 (Pubitemid 24294453)
72. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, Wang X (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5):445-456 (Pubitemid 350064365)
73. Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6(1):9-20 (Pubitemid 40064895)
74. Pichlmair A, Reis e Sousa C (2007) Innate recognition of viruses. Immunity 27(3):370-383
75. Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533
76. Pomerantz JL, Baltimore D (2002) Two pathways to NF-kappaB. Mol Cell 10(4):693-695
77. Qiao G, Li Z, Molinero L, Alegre ML, Ying H, Sun Z, Penninger JM, Zhang J (2008) T cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol 28(7):2470-2480 (Pubitemid 351429990)
78. Richards RM, Lowy DR, Schiller JT, Day PM (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 103(5):1522-1527 (Pubitemid 43191198)
79. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC (2006) Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 106(6):1316-1319 (Pubitemid 43363908)
80. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487-2498
81. Rudolph MG, Stanfield RL, Wilson IA (2006) How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24: 419-466
82. Sato S, Sanjo H, Tsujimura T, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Takeuchi O, Akira S (2006) TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int Immunol 18(10):1405-1411 (Pubitemid 44446818)
83. Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K, Akira S (2003) Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 171(8):4304-4310 (Pubitemid 37238709)
84. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitinprotein ligase in the ubiquitination of p53. Cell 75(3):495-505 (Pubitemid 23335075)
85. Scheffner M, Whitaker NJ (2003) Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 13(1):59-67 (Pubitemid 36269181)
86. Schneider V, Kay S, Lee HM (1983) Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 27(3):220-224 (Pubitemid 13071766)
87. Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, Veenbergen S, Meijer CJ, Hooijberg E (2005) Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol 114(2):119-129 (Pubitemid 40082377)
88. Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E (2003) In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 171(6):2912-2921
89. Schulze-Luehrmann J, Ghosh S (2006) Antigen-receptor signaling to nuclear factor kappa B. Immunity 25(5):701-715 (Pubitemid 46107295)
90. Schwartz AL, Ciechanover A (2009) Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 49:73-96
91. Sen GC (2001) Viruses and interferons. Annu Rev Microbiol 55:255-281
92. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J (2003) Triggering the interferon antiviral response through an IKK-related pathway. Science 300(5622):1148-1151
93. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ (2004) The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14(3):289-301 (Pubitemid 38591401)
94. Sun SC (2008) Deubiquitylation and regulation of the immune response. Nat Rev Immunol 8(7):501-511
95. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:335-376 (Pubitemid 37174535)
96. Tang ED, Wang CY, Xiong Y, Guan KL (2003) A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. J Biol Chem 278(39):37297-37305 (Pubitemid 37175246)
97. Thompson DA, Zacny V, Belinsky GS, Classon M, Jones DL, Schlegel R, Munger K (2001) The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts. Oncogene 20(28):3629-3640 (Pubitemid 32624955)
98. Tungteakkhun SS, Duerksen-Hughes PJ (2008) Cellular binding partners of the human papillomavirus E6 protein. Arch Virol 153(3):397-408
99. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131(4):669-681
100. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131(4):682-693 (Pubitemid 350103599)
101. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12-19 (Pubitemid 29406813)
102. Wan YY, Chi H, Xie M, Schneider MD, Flavell RA (2006) The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol 7(8):851-858 (Pubitemid 44084092)
103. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412(6844):346-351 (Pubitemid 32694385)
104. Wang L, Du F, Wang X (2008) TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133(4):693-703 (Pubitemid 351636305)
105. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430(7000):694-699 (Pubitemid 39061687)
106. Wing SS (2003) Deubiquitinating enzymes-the importance of driving in reverse along the ubiquitin-proteasome pathway. Int J Biochem Cell Biol 35(5):590-605
107. Wu CJ, Ashwell JD (2008) NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc Natl Acad Sci USA 105(8):3023-3028
108. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD (2006) Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation. Nat Cell Biol 8(4):398-406
109. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP (2003) Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 11(6):1445-1456 (Pubitemid 36776532)
110. Yamamoto M, Okamoto T, Takeda K, Sato S, Sanjo H, Uematsu S, Saitoh T, Yamamoto N, Sakurai H, Ishii KJ, Yamaoka S, Kawai T, Matsuura Y, Takeuchi O, Akira S (2006) Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol 7(9):962-970 (Pubitemid 44263910)
111. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S (2003) Role of adaptor TRIF in the MyD88-independent tolllike receptor signaling pathway. Science 301(5633):640-643 (Pubitemid 36927946)
112. Yamamoto M, Sato S, Saitoh T, Sakurai H, Uematsu S, Kawai T, Ishii KJ, Takeuchi O, Akira S (2006) Cutting edge: pivotal function of Ubc13 in thymocyte TCR signaling. J Immunol 177(11):7520-7524 (Pubitemid 44846266)
113. Yang B, Gay DL, MacLeod MK, Cao X, Hala T, Sweezer EM, Kappler J, Marrack P, Oliver PM (2008) Nedd4 augments the adaptive immune response by promoting ubiquitin-mediated degradation of Cbl-b in activated T cells. Nat Immunol 9(12):1356-1363
114. Yang R, Murillo FM, Delannoy MJ, Blosser RL, WHt Yutzy, Uematsu S, Takeda K, Akira S, Viscidi RP, Roden RB (2005) B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 174(12):7912-7919 (Pubitemid 40806301)
115. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99(25):16168-16173 (Pubitemid 35462767)
116. Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S (2000) Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyterecognizing endogenous human papillomavirus antigens. Cancer Res 60(2):365-371 (Pubitemid 30070764)
117. Youde SJ, McCarthy CM, Thomas KJ, Smith KL, Man S (2005) Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer 114(4):606-612 (Pubitemid 40349620)
118. Yuan H, Fu F, Zhuo J, Wang W, Nishitani J, An DS, Chen IS, Liu X (2005) Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene 24(32):5069-5078 (Pubitemid 41129084)
119. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M, Xiao W, Dixit VM (2004) Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 427(6970):167-171 (Pubitemid 38094958)
120. Zhou Q, Mrowietz U, Rostami-Yazdi M (2009) Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 47(7):891-905